These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 32193808)

  • 1. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
    Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
    Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
    Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
    Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
    Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
    Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
    Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W
    Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl2l10, a new Tpx2 binding partner, is a master regulator of Aurora kinase A in mouse oocytes.
    Lee SY; Kim EY; Kim KH; Lee KA
    Cell Cycle; 2016 Dec; 15(23):3296-3305. PubMed ID: 27753540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.
    Orth M; Unger K; Schoetz U; Belka C; Lauber K
    Oncogene; 2018 Jan; 37(1):52-62. PubMed ID: 28869599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
    Xie F; Li C; Zhang X; Peng W; Wen T
    Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer.
    Miwa T; Kokuryo T; Yokoyama Y; Yamaguchi J; Nagino M
    Cancer Med; 2015 Jul; 4(7):1091-100. PubMed ID: 25914189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.
    Wang X; Breuer J; Garbe S; Giordano F; Brossart P; Feldmann G; Bisht S
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRAS
    Tan YQ; Sun B; Zhang X; Zhang S; Guo H; Basappa B; Zhu T; Sethi G; Lobie PE; Pandey V
    Cell Death Dis; 2024 Feb; 15(2):173. PubMed ID: 38409090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AurkA/TPX2 co-overexpression in nontransformed cells promotes genome instability through induction of chromosome mis-segregation and attenuation of the p53 signalling pathway.
    Naso FD; Polverino F; Cilluffo D; Latini L; Stagni V; Asteriti IA; Rosa A; Soddu S; Guarguaglini G
    Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167116. PubMed ID: 38447882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma.
    Xiao Y; Zhang B; Cloyd JM; Xu G; Du S; Mao Y; Pawlik TM
    Surg Oncol; 2022 Sep; 44():101849. PubMed ID: 36116415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
    Sun Y; Peng W; He W; Luo M; Chang G; Shen J; Zhao X; Hu Y
    J Exp Clin Cancer Res; 2018 Jul; 37(1):166. PubMed ID: 30041673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.
    Warner SL; Stephens BJ; Nwokenkwo S; Hostetter G; Sugeng A; Hidalgo M; Trent JM; Han H; Von Hoff DD
    Clin Cancer Res; 2009 Nov; 15(21):6519-28. PubMed ID: 19861455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AurkA nuclear localization is promoted by TPX2 and counteracted by protein degradation.
    Asteriti IA; Polverino F; Stagni V; Sterbini V; Ascanelli C; Naso FD; Mastrangelo A; Rosa A; Paiardini A; Lindon C; Guarguaglini G
    Life Sci Alliance; 2023 May; 6(5):. PubMed ID: 36797043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.